Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults

Journal of Clinical Psychopharmacology

Volumn 32, Issue 3, 2012, Pages 403-407

  Seitz, Dallas P ^a   Campbell, Robert J ^a   Bell, Chaim M ^b,c,d   Gill, Sudeep S ^a   Gruneir, Andrea ^c,d   Herrmann, Nathan ^f   Newman, Alice M ^c   Anderson, Geoff ^c,d,g   Rochon, Paula A ^c,e,g  

^a QUEEN S UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

acute angle closure glaucoma; adverse drug event; antidepressant; observational study

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADULT; AGED; AGING; ARTICLE; BILLING AND CLAIMS; CANADA; CLOSED ANGLE GLAUCOMA; CONTROLLED STUDY; DATA BASE; DEPRESSION; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; GLAUCOMA, ANGLE-CLOSURE; HUMANS; LOGISTIC MODELS; MALE; NATIONAL HEALTH PROGRAMS; NEUROTRANSMITTER AGENTS; ONTARIO; RISK; TIME FACTORS;

EID: 84861031888     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31825420a1     Document Type: Article

References (26)

1. Raymond CB, Morgan SG, Caetano PA. Antidepressant utilization in British Columbia from 1996 to 2004: Increasing prevalence but not incidence. Psychiatr Serv. 2007;58:79-84.
2. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006;1:CD003491.
3. Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults. Arch Intern Med. 2004;164:327-332.
4. Andrade C, Sandarsh S, Chethan KB, et al. Serontonin reuptake inhibitor antidepressants and abnormal bleeding: A review for clinicians and reconsideration of mechanisms. J Clin Psychiatry. 2010;71:1565-1575.
5. Richa S, Yazbek J-C. Ocular adverse effects of common psychotropic agents. CNS Drugs. 2010;24:501-526.
6. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393.
7. Erie JC, Hodge DO, Gray DT. The incidence of primary angle-closure glaucoma in Olmsted County, Minnesota. Arch Ophthalmol. 1997;115:177-181.
8. Foster PJ. The epidemiology of primary angle closure glaucoma and associated glaucomatous optic neuropathy. Semin Ophthalmol. 2002;17:50-58.
9. Costagliola C, Parmeggiani F, Semeraro F, et al. Selective serotonin reuptake inhibitors: A review of its effects on intraocular pressure. Curr Neuropharmacol. 2008;6:293-310.
10. Marchini G, Babighian S, Tosi R, et al. Comparative study of the effects of 2% ibopamine, 10% phenylephrine, and 1% tropicamide on the anterior segment. Invest Ophthalmol Vis Sci. 2003;44: 281-289.
11. Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol. 2007;18:129-133.
12. Ritch R, Krupin T, Henry C, et al. Oral imipramine and acute angle closure glaucoma. Arch Ophthalmol. 1994;112:67-68.
13. Costagliola C, Parmeggiani F, Sebastiani A. SSRIs and intraocular pressure modifications: Evidence, therapeutic implications and possible mechanisms. CNS Drugs. 2004;18:475-484.
14. Williams JI, O'Brien BJ, Sellors C, et al. A summary of studies on the quality of health care administrative databases in Canada. In: Patterns of Health Care in Ontario. The ICES Practice Atlas. Ottawa, ON: Canadian Medical Association; 1996;339-345.
15. Levy AR, O'Brien BJ, Sellors C, et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67-71.
16. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21:193-221.
17. Maclure M. The case-crossover design: A method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133: 144-153.
18. Saw S, Gazzard G, Friedman DS. Interventions for angle-closure glaucoma: An evidence-based update. Ophthalmology. 2003;110:1869-1879.
19. Suissa S. The case-time-control design. Epidemiology. 1995;6(3):248-253.
20. Hebert C, Delaney JAC, Hemmelgarn B, et al. Benzodiazepines and elderly drivers: A comparison of pharmacoepidemiological study designs. Pharmacoepidemiol Drug Saf. 2007;16:845-849.
21. Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161:1099-1105.
22. Mathew R, Chow R, Isaacs D, et al. SSRIs and increased intraocular pressure. Aust Adverse Drug React Bull. 2001;20:3-4.
23. Ezra DG, Storoni M, Whitefield LA. Simultaneous bilateral acute angle closure glaucoma following venlafaxine treatment. Eye. 2006;20:128-129.
24. Ng B, Sanbrook GM, Malouf AJ, et al. Venlafaxine and bilateral acute angle closure glaucoma. Med J Aust. 2002;176:241.
25. Pae CU, Lee CU, Lee SJ, et al. Association of low dose trazodone treatment with aggravated angle-closure glaucoma. Psychiatry Clin Neurosci. 2003;57:127-128.
26. Hauben M, Reich L. Reports of acute angle closure glaucoma-related adverse events with SSRIs: Results of a disproportionality analysis. CNS Drugs. 2006;20:327-329.